• Home
  • Science
    • ImmunoBody®
    • Moditope®
    • Glymab®
    • Publications
  • Pipeline
  • News
  • Investors
    • Share Info
    • Financial Info
    • Documents & Presentations
    • Corporate Governance
  • Contact Us
    • Find a trial
    • Become an Investigator

Annual Report 30th April 2022

by admin | Apr 30, 2022 | Financial Info

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

Modi-1 Phase 1/2 clinical trial open for recruitment

by admin | Apr 13, 2022 | Latest News, Modi-1, Regulatory News

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

Vaccine Can Induce CD4-Mediated Responses to Homocitrullinated Peptides via Multiple HLA-Types and Confer Anti-Tumor Immunity

by admin | Apr 12, 2022 | Moditope, Vaccines

Katherine Cook, Wei Xue, Suha Atabani, Peter Symonds, Abdullah Al Omari, Ian Daniels, Sabaria Shah, Ruhul Hasan Choudhury, Daisy Weston, Rachael Metheringham, Victoria Brentville and Lindy Durrant ABSTRACT: Homocitrullination is the post translation modification (PTM)...

Broadening of COVIDITY Phase 1 clinical trial in South Africa

by admin | Mar 29, 2022 | Covid-19, Latest News, Regulatory News

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

Scancell progresses its new anti-glycan monoclonal antibody (mAb) platform GlyMab™

by admin | Mar 17, 2022 | GlyMab, Latest News

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!
« Older Entries
Next Entries »

Recent Posts

  • Scancell to Present at the H.C. Wainwright 28th Annual Global Investment Conference
  • H.C. Wainwright 28th Annual Global Investment Conference
  • Scancell Receives UK MHRA Clinical Trial Authorization for Phase 3 Registrational Trial of iSCIB1+ in Advanced Melanoma
  • Strategic transactions to unlock longer-term value
  • Scancell and Neuphoria Therapeutics Announce Merger Agreement and Financing

Recent Comments

No comments to show.

Scancell is focused on developing novel immunotherapies for the treatment of cancer and was founded in 1996 based on research led by Professor Lindy Durrant at the University of Nottingham in the UK.

  • Follow
  • Follow

Science
Our Pipeline
News
Contact Us
Find a Trial
Become an Investigator

ACTIVE IMMUNOTHERAPY

ImmunoBody®
Moditope®

ANTIBODIES

GlyMab®
AvidiMab®

Investors
Company Profile
Advisors
Corporate Governance
Documents & Presentations
Share Information
Financial Information

Copyright © 2026 Scancell | Website Designed & Developed by Identity Creative | Privacy & Cookie Policy